Barclays analyst Dan Levy upgraded Visteon to Overweight from Equal Weight with a price target of $145, up from $140. The company’s “outgrowth narratives” should accelerate in a flat production environment, supporting a mid-teen annual EBITDA through 2026, the analyst tells investors in a research note. The firm says that with a “relatively weak valuation reflecting somewhat depressed assumptions,” Visteon has opportunity for recovery to the extent the company can maintain solid growth and margin metrics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VC:
- Visteon to Announce First Quarter 2024 Results on April 25
- Morgan Stanley upgrades U.S. auto industry view to Attractive from In-Line
- Visteon price target lowered to $146 from $188 at RBC Capital
- Visteon price target lowered to $140 from $149 at Citi
- Visteon price target lowered to $148 from $158 at Baird
